Eyenovia (Nasdaq:EYEN) today announced the first commercial sale of Mydcombi, its eye treatment for use with the Optejet delivery device.
In May, the FDA approved the Mydcombi treatment for use with Optejet. New York-based Eyenovia designed Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. Its approval marked the first approved fixed-dose combination of tropicamide and phenylephrine in the U.S.
The FDA nod was also the first for a product using Eyenovia’s proprietary Optejet device.
Get the full story at our sister site, Drug Delivery Business News.